Literature DB >> 10436870

Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

M Peters-Golden1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10436870     DOI： 10.1007/BF02737608

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


× No keyword cloud information.
  48 in total

1.  Inhibition of bleomycin-induced pulmonary fibrosis by nordihydroguaiaretic acid. The role of alveolar macrophage activation and mediator production.

Authors:  S H Phan; S L Kunkel
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

2.  The formation of thromboxane B2, leukotriene B4 and 12-hydroxyeicosatetraenoic acid by alveolar macrophages after activation during tumor growth in the rat.

Authors:  J E Vincent; M A Vermeer; W J Kort; F J Zijlstra
Journal:  Biochim Biophys Acta       Date:  1990-02-06

3.  Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS.

Authors:  A H Stephenson; A J Lonigro; T M Hyers; R O Webster; A A Fowler
Journal:  Am Rev Respir Dis       Date:  1988-09

4.  Alveolar macrophages from patients with asbestos exposure release increased levels of leukotriene B4.

Authors:  J G Garcia; D E Griffith; A B Cohen; K S Callahan
Journal:  Am Rev Respir Dis       Date:  1989-06

5.  Detection of leukotrienes B4, C4 and of their isomers in arterial, mixed venous blood and bronchoalveolar lavage fluid from ARDS patients.

Authors:  M Antonelli; M Bufi; R A De Blasi; G Crimi; G Conti; C Mattia; G Vivino; L Lenti; D Lombardi; A Dotta
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

6.  Atopic children with cystic fibrosis have increased urinary leukotriene E4 concentrations and more severe pulmonary disease.

Authors:  P Greally; A J Cook; A P Sampson; R Coleman; S Chambers; P J Piper; J F Price
Journal:  J Allergy Clin Immunol       Date:  1994-01       Impact factor: 10.793

7.  Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.

Authors:  N F Voelkel; R M Tuder; K Wade; M Höper; R A Lepley; J L Goulet; B H Koller; F Fitzpatrick
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

8.  Increased plasma levels of atrial natriuretic factor, renin activity, and leukotriene C4 in chronic obstructive pulmonary disease.

Authors:  D Piperno; Y Pacheco; R Hosni; P Moliere; C Gharib; M Lagarde; M Perrin-Fayolle
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

9.  Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis.

Authors:  T Ozaki; H Hayashi; K Tani; F Ogushi; S Yasuoka; T Ogura
Journal:  Am Rev Respir Dis       Date:  1992-01

10.  Delayed thromboxane or tumor necrosis factor-alpha, but not leukotriene inhibition, attenuates prolonged pulmonary hypertension in endotoxemia.

Authors:  J X Li; J R Oliver; C Y Lu; J B Philips
Journal:  Am J Med Sci       Date:  1995-09       Impact factor: 2.378
View more
  1 in total

1.  Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis.

Authors:  B Haribabu; M W Verghese; D A Steeber; D D Sellars; C B Bock; R Snyderman
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.